239 related articles for article (PubMed ID: 36495425)
1. Noncoding RNAs associated with IgA nephropathy.
Kademani SP; Nelaturi P; Sathyasagar K; Ravikumar S
J Nephrol; 2023 Apr; 36(3):911-923. PubMed ID: 36495425
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.
Cambier A; Gleeson PJ; Abbad L; Canesi F; da Silva J; Bex-Coudrat J; Deschênes G; Boyer O; Rabant M; Ulinski T; Hogan J; Peuchmaur M; Berthelot L; Monteiro RC
Kidney Int; 2022 Feb; 101(2):274-287. PubMed ID: 34756952
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant immunoglobulin A deposition and nephropathy in allografts.
Sofue T; Suzuki H; Ueda N; Kushida Y; Minamino T
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():4-9. PubMed ID: 29968406
[TBL] [Abstract][Full Text] [Related]
5. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1.
Lai KN; Chan LY; Tang SC; Tsang AW; Li FF; Lam MF; Lui SL; Leung JC
Kidney Int; 2004 Oct; 66(4):1403-16. PubMed ID: 15458433
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
Suzuki H
Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
[TBL] [Abstract][Full Text] [Related]
7. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
8. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of IgA nephropathy.
Lai AS; Lai KN
Curr Mol Med; 2005 Aug; 5(5):475-87. PubMed ID: 16101476
[TBL] [Abstract][Full Text] [Related]
10. Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.
Wang Y; Zhao MH; Zhang YK; Li XM; Wang HY
Clin Exp Immunol; 2004 Apr; 136(1):168-75. PubMed ID: 15030528
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
[TBL] [Abstract][Full Text] [Related]
12. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
Tamouza H; Chemouny JM; Raskova Kafkova L; Berthelot L; Flamant M; Demion M; Mesnard L; Paubelle E; Walker F; Julian BA; Tissandié E; Tiwari MK; Camara NO; Vrtovsnik F; Benhamou M; Novak J; Monteiro RC; Moura IC
Kidney Int; 2012 Dec; 82(12):1284-96. PubMed ID: 22951891
[TBL] [Abstract][Full Text] [Related]
13. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
[TBL] [Abstract][Full Text] [Related]
14. Role of complement in IgA nephropathy.
Daha MR; van Kooten C
J Nephrol; 2016 Feb; 29(1):1-4. PubMed ID: 26567162
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin A1 protease: a new therapeutic candidate for immunoglobulin A nephropathy.
Xie LS; Huang J; Qin W; Fan JM
Nephrology (Carlton); 2010 Aug; 15(5):584-6. PubMed ID: 20649880
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry-based screening identifies circulating immunoglobulinA-α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy.
Xu B; Zhu L; Wang Q; Zhao Y; Jia M; Shi S; Liu L; Lv J; Lai W; Ji J; Zhang H
Nephrol Dial Transplant; 2021 Apr; 36(5):782-792. PubMed ID: 33351144
[TBL] [Abstract][Full Text] [Related]
17.
Dotz V; Visconti A; Lomax-Browne HJ; Clerc F; Hipgrave Ederveen AL; Medjeral-Thomas NR; Cook HT; Pickering MC; Wuhrer M; Falchi M
J Am Soc Nephrol; 2021 Oct; 32(10):2455-2465. PubMed ID: 34127537
[TBL] [Abstract][Full Text] [Related]
18. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
Suzuki Y; Suzuki H; Yasutake J; Tomino Y
Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055
[TBL] [Abstract][Full Text] [Related]
19. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.
Tanaka M; Seki G; Someya T; Nagata M; Fujita T
Clin Dev Immunol; 2011; 2011():470803. PubMed ID: 21318178
[TBL] [Abstract][Full Text] [Related]
20. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
